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To examine the association of glucose-6-phosphate dehydrogenase (G6PD) deficiency
with adolescent physical and mental health, as effects of G6PD deficiency on health are
rarely reported.
Methods
In a population-representative Chinese birth cohort: “Children of 1997” (n = 8,327), we esti-
mated the adjusted associations of G6PD deficiency with growth using generalized estimat-
ing equations, with pubertal onset using interval censored regression, with hospitalization
using Cox proportional hazards regression and with size, blood pressure, pubertal matura-
tion and mental health using linear regression with multiple imputation and inverse probabil-
ity weighting.
Results
Among 5,520 screened adolescents (66% follow-up), 4.8% boys and 0.5% girls had G6PD
deficiency. G6PD-deficiency was not associated with birth weight-for-gestational age or
length/height gain into adolescence, but was associated with lower childhood body mass
index (BMI) gain (-0.38 z-score, 95% confidence interval (CI) -0.57, -0.20), adjusted for sex
and parental education, and later onset of pubic hair development (time ratio = 1.029, 95%
CI 1.007, 1.050). G6PD deficiency was not associated with blood pressure, height, BMI or
mental health in adolescence, nor with serious infectious morbidity until adolescence.
Conclusions
G6PD deficient adolescents had broadly similar physical and mental health indicators, but
transiently lower BMI gain and later pubic hair development, whose long-term implications
warrant investigation.
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Introduction
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme defi-
ciency worldwide affecting 400 million people mainly from Sub-Saharan Africa, the Mediterra-
nean and Southeast Asia with prevalence ranging from 3% to 26%.[1] G6PD is X-linked and
recessive so boys are more susceptible than girls; nonetheless, some girls with heterozygous
genes may also be affected due to randomly occurringunequal inactivation of the X-chromo-
some.[2] Low G6PD affects red blood cells because their defense against oxidative damage
relies heavily on G6PD.[2] G6PD deficiency causes neonatal jaundice and acute hemolytic ane-
mia on exposure to fava beans, infections or certainmedications.[2] G6PD deficiency is
thought to confer protection against malaria,[1] whether such survival trades-off against any
other aspects of fitness[3] is unknown. G6PD catalyses the initiation of the pentose phosphate
pathway generating nicotinamide adenine dinucleotide phosphate (NADPH), so G6PD defi-
ciency limits NADPH production and may inhibit NADPH-dependent pathways. Specially,
G6PD deficiency could inhibit the 3-hydroxy-3-methylglutaryl-coenzymeA (HMG-CoA)
reductase used for cholesterol synthesis,[4, 5] or cytochrome P450 enzymes used for steroid
metabolism,[6] when the HMG-CoA reductase inhibitor, statins, and HMG-CoA reductase
genetic variants, protect against cardiovascular disease[7] and impair glucosemetabolism.[8]
G6PD deficiency can also result in hyperbilirubinwhich could cause brain damage and dys-
function.[9]G6PD deficiencyhas been reported as associated with a higher risk of diabetes in a
large cross-sectional study from Israel using medical records[10] and several small hospital-
based case-control studies,[10–14] although not in a small study from Italy.[15] G6PD defi-
ciency has also been associated with lower risk of cardiovascular diseasemortality in two cross-
sectional studies from Sardinia (Italy),[16, 17] and with lower risk of myocardial infarction in a
case-control study,[4] although associations of G6PD deficiencywith cardiovascular disease
risk factors[18, 19] and all-cause mortality[17, 20] are inconsistent. G6PD deficiencyhas also
been linked with mental illnesses in adults in some case reports/series,[21, 22] and genetic link-
age studies[23–25] but not all.[26–30] Genetic studies are less open to confounding than most
observational studies, nevertheless the evidence concerning effects of G6PD is limited and
potentially biased by design flaws, such as inappropriate selection of controls in case-control
studies. No studies have systematically assessed how G6PD deficiency affects health across the
life-course, especially from an evolutionary biology perspective that early life survival (from
malaria infections)[1]might trade-off against reproduction and/or growth and development.
[3] Here, we examined the associations of G6PD deficiencywith key aspects of physical and
mental health from birth to adolescence including size and growth, blood pressure, and mental
health (as proxies of growth and development), puberty (as a proxy of reproductive success)
and serious infections (as a proxy of immune systemmaintenance) using a large, population-
representative Chinese birth cohort: “Children of 1997” in Hong Kong this ethnically homoge-




Hong Kong’s “Children of 1997” birth cohort is a population representative Chinese birth
cohort (n = 8,327) that covered 88.0% of all births in Hong Kong from April 1, 1997 to May 31,
1997, described in detail elsewhere.[32] The study was initially established to investigate the
effect of secondhand smoke exposure on infant health. Families were recruited at the first post-
natal visit to any of the 49 Maternal and Child Health Centers (MCHCs) in Hong Kong, which
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parents of all newborns are strongly encouraged to attend for free vaccinations and well-baby
checks. Characteristics obtained using a self-administered questionnaire in Chinese at recruit-
ment and subsequent routine visits include maternal and birth characteristics and socioeco-
nomic position (SEP). Passive follow-up via record linkage was instituted in 2005 to obtain
weight and height from birth to 5 years and birth characteristics, including G6PD status, from
the MCHCs (n = 7,999, 96% successfulmatching); annual weight and height and bi-annual
pubertal status (grade 1 (age 6–7 years) onwards), blood pressure (grade 5 (age 10–11 years)
onwards), emotional and behavioral problems (grade 2, 4 and 6 (i.e., ages 7–8, 9–10 and 11–12
years) and self-esteem (grade 4 (age 9–10 years) onwards) from the Student Health Service,
Department of Health, which provides free annual check-ups for all school students (n = 7,809,
94% successfulmatching); and hospital admission records with details on principal diagnosis
code, date of admission and discharge from the Hospital Authority, which provides in-patient
services at minimal cost accounting for 90% of total bed days (n = 7,352, 88% successfulmatch-
ing).[33] Admissions are coded at discharge according to the International Classification of
Diseases,Ninth Version Clinical Modification (ICD-9CM). At the Student Health Service,
height was measured by stadiometer and weight by digital scale. Blood pressure was measured
using an automated oscillometric device, with initial values over the 90th percentile reference
re-checked with a sphygmomanometer and recorded. Pubertal status for breast or genitalia
and pubic hair development was clinically assessed according to the criteria of Marshall and
Tanner and testicular volume assessed by orchidometer. Emotional and behavioral problems
were assessed from the Revised Parent’s Rutter Scales,[34] self-esteem from the Form A of the
Culture-Free Self Esteem Inventories,[35] and depressive symptoms from the Patient Health
Questionnaire-9 (PHQ-9), validated in Chinese adolescents,[36] in Survey II (2010–2012) and
pilots for in-person follow-up.
G6PD status
G6PD status was categorized as “G6PD-deficient” or “non-G6PD-deficient” based on the
MCHC record. In Hong Kong, a free-of-charge universal neonatal screening program assesses
erythrocyteG6PD activity from umbilical cord blood at birth.[31] Parents of newbornswith
G6PD activity below 25% of the mean are informed and followed-up by the Clinical Genetic
Serviceof the Department of Health,[31] who confirmG6PD status based on whole blood spe-
cific enzyme activity testing.
Outcomes
Growth and size. Growth outcomes considered included birth weight, growth rate in
infancy, childhood and at puberty as well as height and BMI at ~15 years. We used birth
weight-for-gestational age z-score relative to sex- and gestational age-specific contemporary
Hong Kong Chinese infants to proxy fetal growth.[37]We used length/height or BMI gain
z-scores during 3 to 9 months for infancy (birth-<2 years) relative to the 2005 WHO growth
standards for 0–5 years[38] and 3 to 7 years for childhood (2-<8 years) and 8 to 15 years for
puberty (8-<16 years) relative to the 2007 WHO growth references for 5–19 years.[39] Each
cohort member had up to 13 length/height or BMI measurements taken at about 3 and 9
months for infancy, at 3, 6 and 7 years for childhood, and at 8, 9, 10, 11, 12, 13, 14 and 15 years
for puberty. Since length/height or BMI reflects an accumulation of prior exposures, we
included initial size at each growth phase (birth weight z-score for infancy, height or BMI z-
score at 9 months for childhood and height or BMI z-score at 7 years for puberty) to identify
gain at each growth phase. Finally, we considered height and BMI z-scores at ~15 years (14-
<16 years).
G6PD Deficiency and Physical and Mental Health
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Puberty. Pubertal outcomes considered were age at onset of puberty, age of menarche and
testicular volume. Age at pubertal onset was defined, as the earliest age when Tanner stage II
for breast or genitalia and pubic hair was recorded. Children with infeasible sequences of
pubertal stages, such as pubertal stage II before pubertal stage I were excluded.
Blood pressure. Systolic and diastolic blood pressure at ~11 (based on the closest mea-
surement available from 9-<12 years) and 13 years (12-<15 years) z-scores relative to age-,
sex- and height-standardized blood pressure standards from the United States National High
Blood Pressure Education Group in 2004[40] were used.
Serious infections. Hospitalizations (including same-day discharge and in-patient admis-
sion for at least 24 hours) for respiratory (and related) infections (principal diagnosis of ICD-
9CM 33, 34.0, 381–2, 460–6, 477, 480–7, 477 or 493), gastrointestinal infections (ICD-9CM
001–009, 535.00, 535.50, 558.9, 538, 535.40 or 787.91) and other infections (ICD-9CM 10–32,
34.1–139, 320–1, 370, 372.0–372.3, 390–2, 540–2, 590, 595, 599.0, 680–6, 771, 780.3, or 780.6)
were considered. Since inclusion of hospitalizations in the immediate neonatal period could
have introduced bias given the average hospital stay for infants delivered by caesarean section
(7.9 days) differed from natural birth (3.0 days), time to first admission was considered from
the first 9 days of life until 12.0 years of age. We also considered infections by age group (i.e., 9
days-6 years and>6–12 years) to reflect diet transitions, motor development and increasing
social contact.
Mental health. Mental health was assessed from Rutter score, self-esteem and PHQ9. Par-
ent-reported Rutter scores at ~11 years (based on the closest measurement available from 9-<12
years) consist of 31 items describing emotional and behavioral difficulties,with each item scored
0 for does not apply, 1 for applies somewhat or 2 for certainly applies. A total score and subscores
for conduct problems (5 items), emotional problems (5 items) and inattention/hyperactivity (3
items) were calculated, where a higher score indicatedmore emotional and behavioral problems.
Self-reported self-esteem scores at ~11 years (9-<12 years) consist of a total score and subscores
for general (perception of self-worth in general) (20 items), social (perception of quality of rela-
tionships with peer) (10 items), academic (perception of ability to academic success) (10 items),
and parent-related (perception of status at home) (10 items) self-esteemwere calculated, where a
lower score indicated lower self-esteem. Self-reportedPHQ-9 scores at ~13 years (12-<15 years)
consist of 9 items describing symptoms and functional impairment, with each item scored 0 for
not at all, 1 for several days, 2 for more than half the days or 3 for nearly every day. A total PHQ-
9 score was calculated, where a higher score indicatedmore depressive symptoms.
Statistical analysis
We assessed the adjusted associations of G6PD deficiencywith birth weight-for-gestational age
z-score, length/height and BMI z-scores gain during infancy, childhood, and puberty using
generalized estimating equations with an exchange working correlation structure adjusted for
initial size. We assessed the adjusted associations of G6PD deficiencywith age at pubertal
onset using interval-censored regression,[41] using a log-normal distribution, from which a
time ratio greater than 1 indicates older age at pubertal onset, while a time ratio less than 1
indicates younger age at pubertal onset. We assessed the adjusted associations of G6PD defi-
ciency with age at menarche, testicular volume, blood pressure at ~11 or ~13 years, height and
BMI z-scores at ~15 years using linear regression.We assessed the adjusted associations of
G6PD deficiencywith Rutter score, self-esteem score and depressive symptom score using neg-
ative binomial regression.We assessed the adjusted associations of G6PD deficiencywith time
to first hospitalization for respiratory infections, gastro-intestinal infections, other infections
and all infections up until 12 years using Cox proportional hazard regression.
G6PD Deficiency and Physical and Mental Health
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We compared baseline characteristics between those with and without G6PD status using
Cohen effect sizes. Confounders included were sex and highest parental education; race/ethnic-
ity was not considered because all cohort participants are Chinese.We used inverse probability
weighting with multiple imputation (IPW/MI) to recover the representativeness of entire sam-
ple based on the complete cases[42] thereby accounting for any selection bias due to missing
G6PD status. We usedmultiple imputation for confounders, although we had<10% missing
for each confounder, based on a flexible additive regression model with predictive mean
matching[43] incorporating data on the exposure, outcomes, confounders, and other covari-
ates (sex, mode of delivery, birth order, secondhand smoke exposure, type of hospital at birth,
mother’s and father’s age, mother’s and father’s birthplace, parental education, household
income, housing).[44]We created 20 imputed datasets and combined them taking into account
variability between and within imputations based on Rubin’s formula.[43]We predicted the
probability of missing G6PD status using logistic regression based on these confounders and
covariates (sex, mode of delivery, secondhand smoke exposure, type of hospital at birth, moth-
er’s birthplace, parental education, household income, housing) to generate the inverse proba-
bility weights. We used weighted regression models, from which sandwich variance estimators
accounting for the weights were presented. A sample R code for implementing the IPW/MI is
available in the S1 Appendix. Among 5,520 adolescents with G6PD status, we performed an
available case analysis, i.e., deleting cases with missing data on variables on an analysis-by-anal-
ysis basis, for each health outcomes. Since G6PD deficiency is more common in boys, as a sen-
sitivity analysis, we also re-examined the associations among 2,949 boys.
Power analysis. Given 153 children (91.5% boys) were G6PD-deficient in this birth
cohort, we estimated the minimum effect size that can be detectedwith 80% power and level of
significance at 0.05. Our study would allow detection of a mean difference of 0.32 in BMI z-
scores, or 0.61 kg/m2 in BMI during childhood.
Statistical analyses were performed using Stata version 10 (Stata Corp, College station,
Texas, USA) and R version 3.0.1 (R Development Core Team, Vienna, Austria).
Ethics approval
Since our participants are children, informed (non-written) consent for the original survey and
subsequent record linkage was obtained from the parents, next of kin, caretakers or guardians
(informants) on behalf of the participants by the informant agreeing and subsequently com-
pleting the questionnaire at enrollment, this manner of obtaining consent was approved by
The University of Hong Kong Medical Faculty Ethics Committee over 20 years ago. Informed
written consent for subsequent Surveys and in-person follow up was obtained from a parent or
guardian, or at ages 18+ years from the participant. Ethical approval for all studies, including
passive follow-up via record linkage, was obtained from the University of Hong Kong-Hospital
Authority Hong Kong West Cluster Joint Institutional ReviewBoard and also, where appropri-
ate, the Ethics Committee of the Department of Health, Government of the Hong Kong Special
Administrative Region.
Results
Of the original 8,327 cohort members, as of January 2014, 27 had permanently withdrawn. The
2,780 adolescents missing G6PD status did not differ from the other 5,520 in terms of sex,
mode of delivery, secondhand smoke exposure, mother’s birthplace, parental education, house-
hold income and housing, but were more likely to be born in public hospitals (S1 Table).
Among the 5,520 adolescents with G6PD status (66% follow-up), 140 (4.8%) boys and 13
(0.5%) girls were G6PD-deficient with a total 72,889 person-years of follow-up (mean 13.2
G6PD Deficiency and Physical and Mental Health
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years, maximum 15.9 years). Table 1 shows that G6PD deficiencywas associated with lower
parental education but not with mode of delivery, secondhand smoke exposure, type of hospi-
tal at birth, mother’s birthplace, household income or type of housing. G6PD deficiencywas
also associated with higher risk of hospital admission for neonatal jaundice (hazard ratios 2.49,
95% confidence interval (CI) 1.19, 5.18) as would be expected.
Table 2 shows that G6PD deficiencywas not associated with birth weight-for-gestational
age z-score or length/height z-score gain from infancy to adolescence, but was associated with
lower childhoodBMI z-score gain, adjusted for sex and parental education. G6PD deficiency




(n = 153) (n = 5,367)
Characteristics No. % No. % P-value
Child’s sex <0.001
Female 13 8.5 2,557 47.7
Male 140 91.5 2,809 52.4
Mode of delivery 0.38
Natural labour 70 48.3 2,774 53.8
Assisted natural labour 30 20.7 899 17.5
Caesarean birth 45 31.0 1,479 28.7
Secondhand smoke exposure 0.43
None 40 28.0 1,443 28.4
Non-parental household smoking 52 36.4 1,964 38.7
Paternal smoking 40 28.0 1,428 28.1
Maternal smoking 11 7.7 239 4.7
Type of hospital at birth 0.75
Public 103 67.8 3,546 66.5
Private or overseas 49 32.2 1,783 33.5
Mother’s birthplace 0.16
Mainland China or elsewhere 61 42.1 1,865 36.4
Hong Kong 84 57.9 3,257 63.6
Highest parental education at recruitment 0.01
Grade 9 or below 55 37.2 1,478 28.3
Grade 10–11 64 43.2 2,229 42.6
Grade 12 or above 29 19.6 1,521 29.1
Household income per head at recruitment a 0.12
1st quintile 38 26.8 889 18.3
2nd quintile 25 17.6 930 19.2
3rd quintile 28 19.7 962 19.8
4th quintile 23 16.2 1,023 21.1
5th quintile 28 19.7 1,053 21.7
Type of housing at recruitment 0.35
Public estate 68 46.9 2,244 43.7
Subsidized home ownership flat 27 18.6 824 16.0
Private flat 50 34.5 2,072 40.3
a Mean (standard deviation) for household income per head at recruitment in quintiles (in Hong Kong dollar; pegged at a rate of 7.8 dollar = 1 U.S. dollar)
were 1st quintile: $1,751 (414), 2nd quintile: $2,849 (319), 3rd quintile: $4,359 (557), 4th quintile: $6,827 (890) and 5th quintile: $15,287 (17,613).
doi:10.1371/journal.pone.0166192.t001
G6PD Deficiency and Physical and Mental Health
PLOS ONE | DOI:10.1371/journal.pone.0166192 November 8, 2016 6 / 14
Table 2. Adjusteda associations of G6PD status with birth weight-for-gestational age z-score for growth during fetal phase, height and body
mass index (BMI) gain z-scores during infancy, childhood and pubertal phases, age at onset of breast or genitalia or pubic hair development
(Tanner stage II), testicular volume, age at menarche and blood pressure at ~11 and ~13 years, height and BMI z-scores at ~15 years in the Hong
Kong’s “Children of 1997” birth cohort, Hong Kong, China, 1997–2010.
Age Outcomes G6PD status n Mean differencec 95% CI Follow-up n (%)
Fetal Birth weight-for- Deficient 153 -0.05 -0.21, 0.11 5,513
gestational age z-score Non-deficient 5,360 Reference (99.9)
Infancy Length gain z-scoreb Deficient 126 -0.01 -0.15, 0.13 4,562
Non-deficient 4,436 Reference (82.6)
BMI gain z-scoreb Deficient 126 0.01 -0.18, 0.19 4,562
Non-deficient 4,436 Reference (82.6)
Childhood Height gain z-scoreb Deficient 139 -0.03 -0.15, 0.09 5,041
Non-deficient 4,902 Reference (91.3)
BMI gain z-scoreb Deficient 139 -0.38 -0.57, -0.20 5,041
Non-deficient 4,902 Reference (91.3)
Puberty Height gain z-scoreb Deficient 143 -0.04 -0.10, 0.01 5,158
Non-deficient 5,015 Reference (93.4)
BMI gain z-scoreb Deficient 143 -0.05 -0.16, 0.07 5,158
Non-deficient 5,015 Reference (93.4)
n Time ratio 95% CI
Age at onset of breast or Deficient 136 1.010 0.987, 1.030 5,105
genitalia development Non-deficient 4,969 1.000 (92.5)
Age at onset of pubic Deficient 138 1.029 1.007, 1.050 5,129
hair development Non-deficient 4,991 1.000 (92.9)
Age at onset of testes Deficient 124 1.008 0.988, 1.030 2,743
development Non-deficient 2,619 1.000 (93.0)
n Mean differencec 95% CI
Testicular size Deficient 125 -0.22 -0.74, 0.30 2,763
Non-deficient 2,638 Reference (93.7)
Age at menarche Deficient 12 -0.36 -0.94, 0.22 1,951
Non-deficient 1,939 Reference (75.9)
11 years Systolic blood pressure Deficient 124 -0.001 -0.17, 0.17 4,771
z-score Non-deficient 4,347 Reference (81.0)
Diastolic blood pressure Deficient 124 0.05 -0.05, 0.14 4,771
z-score Non-deficient 4,347 Reference (81.0)
13 years Systolic blood pressure Deficient 99 0.01 -0.20, 0.21 3,871
z-score Non-deficient 3,772 Reference (70.1)
Diastolic blood pressure Deficient 99 -0.03 -0.14, 0.08 3,871
z-score Non-deficient 3,772 Reference (70.1)
15 years Height z-score Deficient 78 -0.09 -0.27, 0.10 3,123
Non-deficient 3,045 Reference (56.6)
BMI z-score Deficient 78 -0.09 -0.36, 0.17 3,123
Non-deficient 3,045 Reference (56.6)
a Adjusted for sex and highest parental education
b Additionally adjusted for initial size (birth weight z-score for infancy, height or BMI z-score at 9 months for childhood phase, height or BMI z-score at 7
years for pubertal phase)
c Mean difference in z-score: 1 unit change in birth weight-for-gestational age z-score is approximated to 370 grams; 1 unit change in height z-score is
approximated to 2.3 cm at 9 months, 5.6 cm at 7 years and 7.4 cm at 13 years; 1 unit change in body mass index z-score is approximated to 1.5 kg/m2 at 9
months, 1.9 kg/m2 at 7 years and 2.7 kg/m2 at 13 years; 1 unit change in systolic blood pressure z-score is approximated to 10.6 mmHg and 1 unit change in
diastolic blood pressure z-score is approximated to 11.3 mmHg.
doi:10.1371/journal.pone.0166192.t002
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was associated with later onset of pubic hair development, but not with breast or genitalia
development, age at menarche or testicular volume. G6PD was not associated with systolic or
diastolic blood pressure z-scores at ~11 or ~13 years or with height or BMI z-scores at ~15
years. Table 3 shows that G6PD deficiencywas not associated with hospital admission for
respiratory infections, gastro-intestinal infections, or other infections up until 12 years. Table 4
shows that G6PD deficiencywas not associated with behavioral or emotional problems at ~11
years, self-esteem at ~11 years or depressive symptoms at ~13 years. The sensitivity analysis
produced similar patterns of associations among boys, and also indicated lower pubertal height
z-score gain (S2–S4 Tables).
Discussion
In this contemporary, population-representative Hong Kong Chinese birth cohort with exten-
sive longitudinal measurements of physical and mental health across key life stages for growth
and development, G6PD deficiencywas associated with transiently lower childhoodBMI gain
Table 3. Adjusteda associations of G6PD status with time to first hospitalization for respiratory infections, gastrointestinal infections, other
(non-respiratory or non-gastrointestinal) infections and all infections up until 12 years by age group in the Hong Kong’s “Children of 1997” birth
cohort, Hong Kong, China, 1997–2010.
Age Hospitalization G6PD status Case no. Hazard ratios 95% CI
n (%)
9 days to 12 years
Respiratory infections Deficient 37 (24.2%) 0.84 0.63, 1.11
Non-deficient 1,368 (25.5%) 1.00
Gastrointestinal infections Deficient 17 (11.1%) 0.86 0.57, 1.30
Non-deficient 613 (11.4%) 1.00
Other infections Deficient 17 (11.1%) 0.85 0.57, 1.29
Non-deficient 600 (11.2%) 1.00
All infections Deficient 56 (36.6%) 0.88 0.70, 1.11
Non-deficient 1,992 (37.1%) 1.00
9 days to 6 years
Respiratory infections Deficient 32 (20.9%) 0.78 0.58, 1.06
Non-deficient 1,262 (23.5%) 1.00
Gastrointestinal infections Deficient 16 (10.5%) 0.86 0.56, 1.32
Non-deficient 574 (10.7%) 1.00
Other infections Deficient 16 (10.5%) 0.88 0.57, 1.34
Non-deficient 542 (10.1%) 1.00
All infections Deficient 52 (34.0%) 0.88 0.69, 1.11
Non-deficient 1,855 (34.6%) 1.00
6 to <12 years
Respiratory infections Deficient 8 (5.2%) 1.30 0.69, 2.46
Non-deficient 201 (3.8%) 1.00
Gastrointestinal infections Deficient 3 (2.0%) 1.00 0.30, 3.30
Non-deficient 52 (1.0%) 1.00
Other infections Deficient 2 (1.3%) 1.26 0.35, 4.52
Non-deficient 69 (1.3%) 1.00
All infections Deficient 13 (8.5%) 1.18 0.72, 1.93
Non-deficient 303 (5.7%) 1.00
a Adjusted for sex, highest parental education and proxies of preferred service sector (type of hospital at birth and household income per head).
doi:10.1371/journal.pone.0166192.t003
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and later onset of pubic hair development. Otherwise,G6PD-deficient adolescents had similar
current size, blood pressure, risk of serious infectiousmorbidity requiring hospitalization, emo-
tional or behavioral problems, self-esteem or depressive symptoms as others. Results among
boys only were similar. Whether the difference in childhood size gain and pubertal develop-
ment by G6PD status is transient or an indicator of longer term health has yet to be elucidated.
Our findings highlight the need for better understanding of G6PD deficiency across the life
course for the large numbers globally with G6PD.
Despite using prospectively collected height and weight, clinically assessed pubertal devel-
opment, routinely measured blood pressure, physician-diagnosed hospital admission records
and parent- and self-reported psychological outcomes, limitations exists. First, we do not have
erythrocyteG6PD activity, thus cannot assess any graded association with health outcomes.
The prevalence of G6PD deficiency in our study is the level expected in our population,[31] so
we cannot detect very small differences that might be important at a population level even if
not clinically meaningful. Second, population stratification could introduce bias when studying
the associations of G6PD with health across subgroups with different genetic ancestry. Within
an ethnically homogeneous Chinese birth cohort whose parents and grandparents largely origi-
nate from Hong Kong or the neighbouring province of Guangdong, confounding by popula-
tion stratification should be minimal in our setting. Third, althoughmissing G6PD status is
unlikely to differ by child health outcomes, randommisclassificationwould make our results
conservative. Given missing G6PD status was more common among those born in public
Table 4. Adjusteda association of G6PD status with mental health indicated by mean difference in Rutter score at ~11 years, self-esteem score at
~11 years and depressive symptoms score at ~13 years in the Hong Kong’s “Children of 1997” birth cohort, Hong Kong, China, 1997–2010.
Age Outcomes G6PD status n Mean difference 95% CI Follow-up n (%)
11 years Rutter score 3,809
Total Deficient 107 -0.05 -0.17, 0.08 (69.0)
Non-deficient 3,702 Reference
Conduct Deficient 107 0.02 -0.13, 0.17
Non-deficient 3,702 Reference
Emotional Deficient 107 -0.03 -0.20, 0.13
Non-deficient 3,702 Reference
Hyperactivity Deficient 107 -0.17 -0.35, 0.02
Non-deficient 3,702 Reference
11 years Self-esteem score 4,700
Total Deficient 128 0.01 -0.03, 0.04 (85.1)
Non-deficient 4,572 Reference
General Deficient 128 0.003 -0.04, 0.04
Non-deficient 4,572 Reference
Social Deficient 128 -0.01 -0.07, 0.05
Non-deficient 4,572 Reference
Academic Deficient 128 0.02 -0.04, 0.08
Non-deficient 4,572 Reference
Parent-related Deficient 128 0.01 -0.04, 0.06
Non-deficient 4,572 Reference
13 years Depressive symptoms 3,932
PHQ-9 score Deficient 111 0.04 -0.15, 0.22 (71.2)
Non-deficient 3,821 Reference
a Adjusted for sex, highest parental education, age at measurement and survey mode (for PHQ-9).
doi:10.1371/journal.pone.0166192.t004
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hospitals, a particular set of characteristicsmay be under-represented in the included partici-
pants. We used IPW/MI to account for the inclusion probability by assigning a larger weight to
those similar to the excluded based on infant characteristics, family SEP, mother’s birthplace
and a proxy of preferred service use so as to be recover the original sample. Fourth, private hos-
pital admissions are lacking, perhaps mostly likely for families of higher SEP. However, the asso-
ciations of G6PD status with hospitalization did not differ by indicators of preferred service
sector. Our findings would be biased if the association of G6PD with hospitalization differed
among private hospital users, which is unlikely. To account for possible confounding, we
adjusted for these indicators, as adjustment means examining the association separately for pub-
lic hospital users and private hospital users before taking the average. Fifth, follow-up of our
cohort was not complete for health outcomes at different ages, although inclusion of adolescents
with particular combinations of G6PD deficiencyand growth, size, pubertal development, blood
pressure, time to hospitalization and psychological outcomes is unlikely. Sixth, given five differ-
ent traits considered here, as a sensitivity analysis, we re-checked the associations with adjust-
ment for multiple comparisons, using a Bonferroni corrected significance level of 0.01 (0.05/5) to
account for testing 5 traits. G6PD-deficiencyremained associatedwith lower childhoodBMI
gain (-0.38 z-score, 99% CI -0.64, -0.15) and later onset of pubic hair development (time
ratio = 1.029, 99% CI 1.000, 1.058), adjusted for sex and parental education. Finally, we are lim-
ited by the age of the cohort, so we could not consider cardiovascular disease and diabetes as out-
comes.Whether the effect of G6PD deficiencyon chronic diseases could becomemore evident in
adulthood requires future follow-up. We also did not assess the known link of G6PD deficiency
with acute hemolytic anemia because this birth cohort is population-representative and hence
has insufficient cases of serious complications for a relatively rare condition such as G6PD.
This is the first study addressing G6PD deficiency and health beyond early infancy. The null
association of G6PD deficiencywith emotional and behavioral problems, self-esteem and
depressive symptoms in late childhood and early adolescence, together with the conflicting
findings from case reports/series of adult psychiatric patients or genetic linkage studies[21–30]
suggests G6PD deficiency is unlikely to cause mental health problems. Further follow-up of
adult mental health and replication in other settings would provide evenmore reassurance.
G6PD deficiencywas not associated with adolescent blood pressure or size, consistent with our
previous finding that blood pressure is more associated with pubertal rather than earlier size
[45] and with no association of G6PD status with adult blood pressure observed elsewhere.[19]
Lower childhoodBMI gain may simply delay pubertal onset. However, G6PD deficiency affects
the NADPH pathway that is required for cytochrome P450 enzymes to metabolize steroids,[6]
consistent with our findings of specifically later pubic hair development driven by androgens
[46] in G6PD-deficient boys. Earlier adrenarche is associated with higher blood erythrocyte
count and higher hemoglobin.[47]Whether reduced erythrocytemetabolism in G6PD defi-
ciency[48] could be partly due to lower adrenal androgens has not been previously been con-
sidered. Nevertheless such a hypothesis would provide an underlying explanation for G6PD
deficiency, or other exposures, such as statins, having different associations with cardiovascular
disease[4, 16, 17] and diabetes,[10–14] because androgens have different effects on cardiovas-
cular disease[49] and glucosemetabolism,[50, 51] as well as potentially representing the evolu-
tionary biology trade-off of survival (here frommalaria) against reproductive success
consistent with life-history theory.[3]
Conclusions
In an economically developed setting, reassuringly G6PD deficiencyhad little impact on a
range of physical and mental health indicators from birth to adolescence, although an
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association with lower childhoodBMI and later pubic hair development in boys is possible.
Whether such a difference is transient and whether G6PD deficiency affects health, particularly
non-communicable diseases, in adulthood requires large-scaled prospective cohort studies
with reliable G6PD status. Our findings would be useful to formulate evidenced-basedadvices
for re-assuring parents that G6PD deficiencyhas minimal effects on many health outcomes in
childhood. Equally important, this study helps generate discussion among clinical and public
health practitioners concerning the lifelong health impact of G6PD deficiency.
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